<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-99151</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">No disponible</dc:title>
<dc:description xml:lang="en">Vancomycin is widely used in haemodialysis (HD) patients for treating infections of vascular access due to St. Aureus. To avoid subtherapeutic levels it is important to know the adequate dosing in patients undergoing haemodialysis with high flux membranes. Objective: The aim of this study was to evaluate whether HD patients treated with 1 g intravenous (IV) vancomycin reached optimum plasma levels. Material and methods: In a crossover design we studied 28 chronic HD patients, 3 times a week, treated with vancomycin between 15/2/2006 and 14/2/2007. Antibiotic wasgiven at dose of 1 g during the last hour of dialysis session. Plasma levels of vancomycin were measured immediately before next HD (preHD1) and after (postHD1), and prior to the beginning of the second next session (preHD2). We evaluated age, sex, dry height, week Kt/V and the type of membrane used. Results: Of 28 patients, 5 were analysed 3 times, 2 were analysed twice and 9 were analysed once. There were 43 samples, 19 men (44.2%) and 24 women (55.8%), with a mean age of 70 ± 8,4 years. 1 g dose is equivalent to &gt; 15 mg/kg in 31 patients (72.1%) and &lt; 15 mg/kg in 12 (27.9%). The type of membrane used was high flux polyetersulfone (PES-AP) (44.2%), eval (7%), medium-low polyetersulfone (PES-BP) (32.5%) and polyacrylonitrile (16.3%). PreHD1 mean concentration results for the total population was 7.06 mg/ml, being 16.3% bellow optimum levels. There were not difference between patients treated with dose &gt; 15 mg/kg (7.5 mg/ml) and &lt; 15 mg/kg (6 m/ml). When the dose administered was &gt; 15 mg/kg, 6.45% results were subtherapeutic, whereas if the dose was &lt; 15 mg/kg, 41.67% values were bellow optimum levels (p &lt; 0.05). With regard to the dialyzers used, the lowest concentrations were observed with PES-AP (5.95 mg/ml) and the highest values were observed with PES-BP (7.27 mg/ml) (p no significance). No patient using PESBP versus 31.58% patients using PES-AP showed suboptimum values (p = 0,07). All postHD1 and preHD2 results were in subtherapeutic range (mean values, dose &gt; and &lt; 15 mg/kg and all types of membrane). Conclusions: Based on the above results, the vancomycin dosing schedule of 1 g IV every 5-7 days is not recommended for patients undergoing haemodialysis with high flux membranes. Since there are not guidelines for handling this antibiotic in these patients our findings suggest that it may be necessary to monitorize predialysis plasma levels to avoid subtherapeutic values (AU)</dc:description>
<dc:creator>Martínez Sánchez, J</dc:creator>
<dc:creator>Suárez Santisteban, MA</dc:creator>
<dc:creator>González Castillo, P.M</dc:creator>
<dc:creator>Gallego, S</dc:creator>
<dc:creator>Castellano, I</dc:creator>
<dc:creator>Covarsí, A</dc:creator>
<dc:creator>Marigliano, N</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Dado el amplio uso de vancomicina en hemodiálisis (HD) es necesario adecuar la dosificación a las actuales membranas de diálisis, asegurando niveles óptimos. Objetivo: Valorar si, en HD, tras 1 gramo intravenoso (IV) los niveles plasmáticos de vancomicina se encuentran en rango terapéutico. Material y métodos: Estudio de cohorte transversal que incluye 28 pacientes en HD 3 veces/semana tratados con vancomicina entre el 15/2/2006 y el 14/2/2007. Sead ministró 1 gramo IV durante la última hora de HD, determinando niveles antes y después de la sesión siguiente(preHD1, postHD1) y antes de la 2ª sesión siguiente(preHD2). Resultados: De los 28 pacientes, 5 presentaban 3determinaciones y 5 presentaban 2 y el resto 1. De las 43muestras, 19 eran hombres (44,2%) y 24 mujeres (55,8%),con edad media 70 ± 8,4 años. La dosis de 1 gramo correspondía a &gt; 15 mg/kg en 31 pacientes (72,1%) y &lt; 15 mg/kgen 12 (27,9%). El 44,2% utilizaban polietersulfona de alta permeabilidad (PES-AP), 7% eval, 32,5% polietersulfona de media-baja permeabilidad (PES-BP) y 16,3% poliacrilonitrilo. El nivel medio preHD1 fue 7,06 mcg/ml, 7,5 mcg/mlpara la dosis &gt; 15 mg/kg y 6 mcg/ml para &lt; 15 mg/kg (p &lt;0,05). El 16,3% presentó niveles por debajo del rango terapéutico, siendo 6,45% para una dosis &gt; 15 mg/kg frente a 41,67% para la dosis &lt; 15 mg/kg. Respecto a los dializadores, los niveles más bajos se observaron con PES-AP (5,95 mcg/ml) y los más elevados con PES-BP (7,27 mcg/ml) (p no significativa). Ningún paciente con PES-BP se encontró en rango infraterapéutico, frente a 31,58% con PES-AP (p = 0,07). Los valores postHD1 y preHD2 se encontraban en niveles subóptimos, tanto la media como los que recibían &gt; 15 mg/kg y &lt; 15 mg/kg, y en todos los dializadores. Conclusiones: La administración de 1 gramo IV de vancomicina cada 5-7 días no es adecuado para pacientes en HD, sobre todo cuando se utilizan membranas de alto flujo. Mientras no se actualizan las pautas de dosificación es necesario monitorizar los niveles prediálisis del fármaco para evitar concentraciones infraterapéuticas (AU)</dc:description>
<dc:source>Nefrologia;28(6): 606-612, nov.-dic. 2008. tab</dc:source>
<dc:identifier>ibc-99151</dc:identifier>
<dc:title xml:lang="es">Dosificación de vancomicina en pacientes en hemodiálisis</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d30037^s22045</dc:subject>
<dc:subject>^d29407^s22045</dc:subject>
<dc:subject>^d4364</dc:subject>
<dc:subject>^d50497^s22067</dc:subject>
<dc:subject>^d23606^s22078</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23504^s22000</dc:subject>
<dc:type>article</dc:type>
<dc:date>200812</dc:date>
</metadata>
</record>
</ibecs-document>
